Here's Why You Should Add Hill-Rom To Your Portfolio Now
Zacks Investment Research | Feb 11, 2020 07:59AM ET
Hill-Rom (NYSE:HRC) is progressing well with growth strategies like acquisitions and product launches. The company’s progress in digital health segment has also bolstered prospects.
This $7.25-billion global medical device company’s earnings growth is estimated to be 11.1% over the next five years. Also, the company has a trailing-four quarter positive earnings surprise of 2.9%, on average.
Robust Q1 Earnings
Hill-Rom exited the first quarter of fiscal 2020 with better-than-expected earnings and in-line revenues. Core revenue growth was 6% year over year, at the high end of its guidance. This reflected the seventh consecutive quarter of mid-single-digit or higher growth. The company saw robust domestic growth, driven by sturdy performance by Patient Support Systems. There was strong double-digit growth in Latin America and China for the second consecutive quarter.
Let’s delve deeper into the other factors that substantiate the company’s Zacks Rank #2 (Buy).
Acquisitions to Add Value: Hill-Rom’s merger and acquisition pipeline continues to remain robust. In the second half of fiscal 2019, the company acquired Breathe Technologies, a developer and manufacturer of a patented nasal cannula technology that enables improved patient mobility. Hill-Rom is now in its early days of re-launching the Breathe Life2000 device, leveraging the company’s vertically-integrated direct commercial model with a disruptive non-invasive respiratory therapy for patients in both acute and home settings. This acquisition is expected to continue driving growth for the company through rest of fiscal 2020.
Focus on Expansion Through Innovation: For quite some time now, Hill-Rom has been focusing on expansion through product development, which is reflected in its rising research and development expenditure. Recently, the company introduced several products, including RetinaVue 700 Imager, EarlySense and WatchCare. In the second half of fiscal 2020, the company is looking forward to a steady cadence of six key new product launches across all three business units. This includes future digital offerings focused on patient falls and deterioration, digital physical assessment tools, and a new mobile operating room table.
Progress in Digital Health Space: Hill-Rom recently launched a smartphone application — Linq mobile. Per the company, the platform has integrated Clinical Workflows with Nurse Call and clinical surveillance with monitoring systems to enhance care team communication and efficiency. This move will pave the way for an additional market opportunity of around $200 million. The company also partnered with Microsoft (NASDAQ:MSFT) to bring together Hill-Rom's extensive clinical knowledge as well as streaming operational data from medical devices and Microsoft's cloud, including Azure IoT and Azure Machine Learning.
However, the company is facing certain downsides like persistent decline in blood center revenues, economic uncertainty and tough competition. In the past year, the stock has underperformed its Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.